Why it may matterVerify against the original reporting
Solid Q2 outperformance on Greenbrook, margin expansion, and a clear profitability trajectory support a near-term stock re-rating, especially as the Go-To-Market improvements are evidenced; however, the sustained cash burn remains a hurdle that could cap upside absent cash-flow improvement.
AI summary
What happened, with direct paths to the underlying reporting
Neuronetics posted a solid Q2 2026, led by Greenbrook’s revenue growth and improved gross margins, signaling a path toward profitability. Management also added CFO Nir Naor and other leadership to accelerate execution, even as cash burn remains a near-term headwind. The 2026 guidance underscores growth potential but keeps cash outflow in focus.
Q2 2026 total revenue: $41.6M; Greenbrook revenue $26.9M, up 16.8% YoY.
Gross margin rose to 51.1% from 46.6%, aided by new go-to-market and ARCM.
Net loss narrowed to $3.4M; Adjusted EBITDA positive at $0.3M.
Cash burn improved: net cash used in ops and investing $1.4M in Q2.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Neuronetics' Greenbrook TMS acquisition transforms it into a vertically integrated mental-health platform, adding TMS and Spravato. The Q1 beat and BTIG's Buy rating with a $5 tar…
Neuronetics to acquire Greenbrook in all-stock deal to enhance NeuroStar's reach. Merger expected to boost revenue growth and deliver $15 million in annual cost savings. Global me…